304am永利集团|·主頁(歡迎您)

Be the most trusted biotech company

2019-10-17

Henlius Innovative Anti-cMET Monoclonal Antibody HLX55 Received Clinical Approval from NMPA
2019-10-12

The breakthrough of China-manufactured trastuzumab biosimilar (HLX02) for metastatic breast cancer︱Interview of Prof. Binghe Xu and Prof. Igor Bondarenko at ESMO Congress 2019
2019-10-09

Top Dialogue | Prof. Yuankai Shi &. Prof. J. Fitzgibbon: Efficacy and the outlook of HLX01（Hanlikang®）in non-Hodgkin’s lymphoma.
2019-09-30

Henlius and KG Bio Enter into Exclusive License Agreement for Henlius Novel Anti-PD-1 mAb HLX10
2019-09-12

Henlius and KG Bio Announce a Collaboration for Henlius Novel Anti-PD-1 mAb HLX10 in the Asia Pacific Region
2019-09-07

The Confirmatory Phase 3 Study Results of First China-Manufactured Trastuzumab Biosimilar, HLX02, will be Presented at Both CSCO and ESMO This Year
2019-08-30

2019 ESMO Henlius Abstract Release
2019-08-20

Monoclonal Antibody HLX10 in Patients with Metastatic MSI-H/dMMR Solid Tumors
2019-08-14

First Patient Dosed in Global Phase 3 Clinical Trial of HLX10 in Combination with Chemotherapy in Patients with Metastatic Squamous NSCLC